Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

 Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US

Shots:

  • Generic launch of Pfizer’s Depo-Provera, Medroxyprogesterone Acetate (MPV) IV 150mg, is a Single-Dose Vial, which is in response to the FDA’s ANDA approval for the drug
  • The launch will support the birth control rate in the US, with safety concerns of not using it more than 2 years as can lead to lose of bone mineral density
  • According to IQVIA, Mylan has 179 ANDAs having pending FDA approval with ~$89.3B annual brand sales and in 31 July, 2018 MPA’s sales in the US was ~$181M

Click here to read full press release/ article | Ref: Mylan | Image: WVNews

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post